TCA
AZN icon

Taconic Capital Advisors’s AstraZeneca AZN Stock Holding History

Taconic Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-450,000
Closed -$44.7M – 487
2021
Q1 		$44.7M Buy
+450,000
New +$45.2M 1.41% 14

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Taconic Capital Advisors's AZN Position: Q1 2021 in Review

Taconic Capital Advisors sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 265,538 shares — an estimated $26.7M sold.

Taconic Capital Advisors first reported a position in AZN in Q4 2020 and held it in 1 quarter. The position peaked at $26.5M in Q4 2020. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

  • Taconic Capital Advisors reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
  • Taconic Capital Advisors sold 265,538 AstraZeneca shares in Q1 2021, an estimated $26.7M.
  • Taconic Capital Advisors first reported a position in AstraZeneca in Q4 2020 and held it in 1 quarter.
  • Taconic Capital Advisors's AstraZeneca position peaked at $26.5M in Q4 2020.
  • 756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Taconic Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.